45 CFR § 180 compliance
C · 70
This hospital published part of what § 180 requires.
●Machine-readable file published: assessment threshold met
○Gross / standard charges: below assessment threshold
●Discounted cash price: assessment threshold met
●Payer-specific negotiated rates: assessment threshold met
○Min / max negotiated charges: below assessment threshold
●Free, public, no login required: assessment threshold met
Procedures listed
5,610
Insurances with rates
13
CPT / HCPCS codes
3,617
Most expensive procedures (gross)
J0225
$483,507
Vutrisiran 25 Mg/0.5 Ml Syring
Gross
$537,229
J0225
$483,507
Vutrisiran 25 Mg/0.5 Ml Syring
Gross
$537,229
J2350
$80,167
Ocrelizumab 300 Mg/10 Ml
Gross
$89,074
J2350
$80,167
Ocrelizumab 300 Mg/10 Ml
Gross
$89,074
J9350
$72,448
Mosunetuzumab-Axgb 30 Mg/30 Ml
Gross
$80,498
J9350
$72,448
Mosunetuzumab-Axgb 30 Mg/30 Ml
Gross
$80,498
J3241
$66,374
Teprotumumab-Trbw 500 Mg Vial
Gross
$73,749
J3241
$66,374
Teprotumumab-Trbw 500 Mg Vial
Gross
$73,749
J9298
$59,888
Nivolum/Relatlim 240-80Mg 113G
Gross
$66,542
J9298
$59,888
Nivolum/Relatlim 240-80Mg 113G
Gross
$66,542
J3245
$51,109
Tildrakizumab-ASMN 100Mg/Ml Sy
Gross
$56,787
J3245
$51,109
Tildrakizumab-ASMN 100Mg/Ml Sy
Gross
$56,787
J9042
$47,655
Brentuximab Vedotin 50 MG Vial
Gross
$52,950
J9042
$47,655
Brentuximab Vedotin 50 MG Vial
Gross
$52,950
J9272
$47,101
Dostarlimab-Gxly 500 Mg/10 Ml
Gross
$52,334
J9272
$47,101
Dostarlimab-Gxly 500 Mg/10 Ml
Gross
$52,334
J9022
$44,469
Atezolizumab 1200 Mg/20 Ml Vl
Gross
$49,409
J9022
$44,469
Atezolizumab 1200 Mg/20 Ml Vl
Gross
$49,409
J9119
$42,437
Cemiplimab-Rwlc 350 Mg/7 Ml Vl
Gross
$47,152
J9119
$42,437
Cemiplimab-Rwlc 350 Mg/7 Ml Vl
Gross
$47,152
J2327
$40,960
Risankizumab-Rzaa 600 Mg/10 Ml
Gross
$45,511
J2327
$40,960
Risankizumab-Rzaa 600 Mg/10 Ml
Gross
$45,511
J9144
$40,653
Daratumumab Hyaluronida 1800Mg
Gross
$45,169
J9144
$40,653
Daratumumab Hyaluronida 1800Mg
Gross
$45,169
J1930
$38,861
Lanreotide Acet 120MG/0.5ML Sy
Gross
$43,179
J1930
$38,861
Lanreotide Acet 120MG/0.5ML Sy
Gross
$43,179
J9316
$36,016
Pertuzu-Trastuzu 10 Ml Vial
Gross
$40,017
J9316
$36,016
Pertuzu-Trastuzu 10 Ml Vial
Gross
$40,017
J3380
$35,670
Vedolizumab 300 MG Vial
Gross
$39,633
J3380
$35,670
Vedolizumab 300 MG Vial
Gross
$39,633
J9228
$35,315
Ipilimumab 5 MG/ML 10 ML Vial
Gross
$39,239
J9228
$35,315
Ipilimumab 5 MG/ML 10 ML Vial
Gross
$39,239
J9301
$33,729
Obinutuzumab 1000 MG/40ML Vial
Gross
$37,476
J9301
$33,729
Obinutuzumab 1000 MG/40ML Vial
Gross
$37,476
Q4104
$30,408
Dressing Bio Intgr 250SqCM Msh
Gross
$33,787
Q4104
$30,408
Dressing Bio Intgr 250SqCM Msh
Gross
$33,787
J3101
$28,426
Tenecteplase 50 Mg/10 Ml Syrng
Gross
$31,584
J3101
$28,426
Tenecteplase 50 Mg/10 Ml Syrng
Gross
$31,584
J9306
$26,828
Pertuzumab 420 MG/14 ML Vial
Gross
$29,809
J9306
$26,828
Pertuzumab 420 MG/14 ML Vial
Gross
$29,809
J9271
$23,392
Pembrolizumab 100 MG/4 ML Vial
Gross
$25,990
J9271
$23,392
Pembrolizumab 100 MG/4 ML Vial
Gross
$25,990
J0717
$23,298
Certolizumab Pegol 400 Mg Kit
Gross
$25,886
J0717
$23,298
Certolizumab Pegol 400 Mg Kit
Gross
$25,886
J0491
$21,160
Anifrolumab-FNIA 300Mg/2Ml Via
Gross
$23,511
J0491
$21,160
Anifrolumab-FNIA 300Mg/2Ml Via
Gross
$23,511
77301
$18,823
IMRT Planning
Gross
$20,914
77301
$18,823
IMRT Planning
Gross
$20,914
J2506
$18,437
Pegfilgrastim 6 MG/0.6 ML Syr
Gross
$20,486
J2506
$18,437
Pegfilgrastim 6 MG/0.6 ML Syr
Gross
$20,486
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J0225 | Vutrisiran 25 Mg/0.5 Ml Syring | $537,229 | $483,507 | — | — | 3 |
| J0225 | Vutrisiran 25 Mg/0.5 Ml Syring | $537,229 | $483,507 | — | — | 6 |
| J2350 | Ocrelizumab 300 Mg/10 Ml | $89,074 | $80,167 | — | — | 3 |
| J2350 | Ocrelizumab 300 Mg/10 Ml | $89,074 | $80,167 | — | — | 8 |
| J9350 | Mosunetuzumab-Axgb 30 Mg/30 Ml | $80,498 | $72,448 | — | — | 3 |
| J9350 | Mosunetuzumab-Axgb 30 Mg/30 Ml | $80,498 | $72,448 | — | — | 6 |
| J3241 | Teprotumumab-Trbw 500 Mg Vial | $73,749 | $66,374 | — | — | 3 |
| J3241 | Teprotumumab-Trbw 500 Mg Vial | $73,749 | $66,374 | — | — | 6 |
| J9298 | Nivolum/Relatlim 240-80Mg 113G | $66,542 | $59,888 | — | — | 3 |
| J9298 | Nivolum/Relatlim 240-80Mg 113G | $66,542 | $59,888 | — | — | 6 |
| J3245 | Tildrakizumab-ASMN 100Mg/Ml Sy | $56,787 | $51,109 | — | — | 3 |
| J3245 | Tildrakizumab-ASMN 100Mg/Ml Sy | $56,787 | $51,109 | — | — | 6 |
| J9042 | Brentuximab Vedotin 50 MG Vial | $52,950 | $47,655 | — | — | 3 |
| J9042 | Brentuximab Vedotin 50 MG Vial | $52,950 | $47,655 | — | — | 6 |
| J9272 | Dostarlimab-Gxly 500 Mg/10 Ml | $52,334 | $47,101 | — | — | 3 |
| J9272 | Dostarlimab-Gxly 500 Mg/10 Ml | $52,334 | $47,101 | — | — | 6 |
| J9022 | Atezolizumab 1200 Mg/20 Ml Vl | $49,409 | $44,469 | — | — | 3 |
| J9022 | Atezolizumab 1200 Mg/20 Ml Vl | $49,409 | $44,469 | — | — | 8 |
| J9119 | Cemiplimab-Rwlc 350 Mg/7 Ml Vl | $47,152 | $42,437 | — | — | 3 |
| J9119 | Cemiplimab-Rwlc 350 Mg/7 Ml Vl | $47,152 | $42,437 | — | — | 7 |
| J2327 | Risankizumab-Rzaa 600 Mg/10 Ml | $45,511 | $40,960 | — | — | 3 |
| J2327 | Risankizumab-Rzaa 600 Mg/10 Ml | $45,511 | $40,960 | — | — | 8 |
| J9144 | Daratumumab Hyaluronida 1800Mg | $45,169 | $40,653 | — | — | 3 |
| J9144 | Daratumumab Hyaluronida 1800Mg | $45,169 | $40,653 | — | — | 8 |
| J1930 | Lanreotide Acet 120MG/0.5ML Sy | $43,179 | $38,861 | — | — | 3 |
| J1930 | Lanreotide Acet 120MG/0.5ML Sy | $43,179 | $38,861 | — | — | 6 |
| J9316 | Pertuzu-Trastuzu 10 Ml Vial | $40,017 | $36,016 | — | — | 3 |
| J9316 | Pertuzu-Trastuzu 10 Ml Vial | $40,017 | $36,016 | — | — | 8 |
| J3380 | Vedolizumab 300 MG Vial | $39,633 | $35,670 | — | — | 3 |
| J3380 | Vedolizumab 300 MG Vial | $39,633 | $35,670 | — | — | 8 |
| J9228 | Ipilimumab 5 MG/ML 10 ML Vial | $39,239 | $35,315 | — | — | 3 |
| J9228 | Ipilimumab 5 MG/ML 10 ML Vial | $39,239 | $35,315 | — | — | 7 |
| J9301 | Obinutuzumab 1000 MG/40ML Vial | $37,476 | $33,729 | — | — | 3 |
| J9301 | Obinutuzumab 1000 MG/40ML Vial | $37,476 | $33,729 | — | — | 8 |
| Q4104 | Dressing Bio Intgr 250SqCM Msh | $33,787 | $30,408 | — | — | 3 |
| Q4104 | Dressing Bio Intgr 250SqCM Msh | $33,787 | $30,408 | — | — | 5 |
| J3101 | Tenecteplase 50 Mg/10 Ml Syrng | $31,584 | $28,426 | — | — | 3 |
| J3101 | Tenecteplase 50 Mg/10 Ml Syrng | $31,584 | $28,426 | — | — | 8 |
| J9306 | Pertuzumab 420 MG/14 ML Vial | $29,809 | $26,828 | — | — | 3 |
| J9306 | Pertuzumab 420 MG/14 ML Vial | $29,809 | $26,828 | — | — | 8 |
| J9271 | Pembrolizumab 100 MG/4 ML Vial | $25,990 | $23,392 | — | — | 3 |
| J9271 | Pembrolizumab 100 MG/4 ML Vial | $25,990 | $23,392 | — | — | 10 |
| J0717 | Certolizumab Pegol 400 Mg Kit | $25,886 | $23,298 | — | — | 3 |
| J0717 | Certolizumab Pegol 400 Mg Kit | $25,886 | $23,298 | — | — | 6 |
| J0491 | Anifrolumab-FNIA 300Mg/2Ml Via | $23,511 | $21,160 | — | — | 3 |
| J0491 | Anifrolumab-FNIA 300Mg/2Ml Via | $23,511 | $21,160 | — | — | 6 |
| 77301 | IMRT Planning | $20,914 | $18,823 | — | — | 3 |
| 77301 | IMRT Planning | $20,914 | $18,823 | — | — | 9 |
| J2506 | Pegfilgrastim 6 MG/0.6 ML Syr | $20,486 | $18,437 | — | — | 3 |
| J2506 | Pegfilgrastim 6 MG/0.6 ML Syr | $20,486 | $18,437 | — | — | 6 |
Showing top 50 of 5,610 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.